Skip to main content
    K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.03
    -0.27 (-2.62%)

    Market Cap: $202.13M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Keros Therapeutics Inc (KROS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Keros Therapeutics are Protara Therapeutics (TARA), Rocket Pharmaceuticals (RCKT) and Kyverna Therapeutics, Inc. Common Stock (KYTX). By market cap, Keros Therapeutics ranks 8th of the 13 companies on this page; Kyverna Therapeutics, Inc. Common Stock (KYTX) is the largest at $319.27M.

    Peer Comparison

    KROS's revenue growth of 180.5% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Keros Therapeutics (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Kyverna Therapeutics, Inc. Common Stock (KYTX)$319.27MN/AN/A0.0%-81.5%0.0%0.00%
    Korro Bio, Inc. (KRRO)$186.81MN/A175.8x0.0%-82.8%-43.1%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Pyxis Oncology Inc (PYXS)$188.98MN/A11.6x0.0%N/A0.0%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Immuneering Corp (IMRX)$240.27MN/AN/A0.0%N/A-99.8%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Peer median$233.78MN/A11.6x0.0%-44.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Keros Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Kyverna Therapeutics, Inc. Common Stock (KYTX)
    Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health...
    KYTX competitors
    Korro Bio, Inc. (KRRO)
    Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare...
    KRRO competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Pyxis Oncology Inc (PYXS)
    Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)...
    PYXS competitors
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Immuneering Corp (IMRX)
    Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its...
    IMRX competitors
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors

    Frequently Asked Questions About KROS

    Who are Keros Therapeutics' main competitors?

    The companies most similar to Keros Therapeutics include Protara Therapeutics (TARA), Rocket Pharmaceuticals (RCKT), Kyverna Therapeutics, Inc. Common Stock (KYTX), Korro Bio (KRRO) and Bicycle Therapeutics (BCYC), listed from the closest match.

    Who is Keros Therapeutics' biggest competitor?

    Kyverna Therapeutics, Inc. Common Stock (KYTX) is the largest of the similar companies at $319.27M; Protara Therapeutics (TARA) is the closest match by business profile, size, sector and industry.

    How does KROS stock compare with its competitors?

    KROS' P/S is 4.9x against a peer median of 11.6x; its net margin is -151.4% against a peer median of 0.0%.

    Which of Keros Therapeutics' competitors pays a higher dividend?

    Keros Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Keros Therapeutics bigger than its competitors?

    No. Keros Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Kyverna Therapeutics, Inc. Common Stock (KYTX) at $319.27M.